Receptor News and Research

RSS

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

17 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Positive results from Winston Laboratories' Civamide Patch trial

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN).

16 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease.

16 Nov 2009

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients on aspirin and the most commonly used, irreversible anti-platelet drug, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Chronic pain patients with depression three times more likely to receive opioid medications

Chronic pain patients with a history of depression are three times more likely to receive long-term prescriptions for opioid medications like Vicodin compared to pain patients who do not suffer from depression, according to new research.

16 Nov 2009

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA.

13 Nov 2009

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses.

13 Nov 2009

Lipid that accumulates in brain cells drives cell death, says research

The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators.

13 Nov 2009

Scientists to develop a treatment for rare genetic disorder, FOP

An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton.

13 Nov 2009

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

13 Nov 2009

OPKO Health acquires NK-1 compounds from Schering

OPKO Health, Inc. today announced that it has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co., Inc. ("Schering").

11 Nov 2009

New microplate for BioFlux live cell imaging workstations

Fluxion Biosciences introduces a new microplate for its BioFlux live cell imaging workstations, extending their shear flow limits to simulate a variety of pathological vascular conditions. With the new High Shear Plate, the BioFlux systems can be an effective tool in thrombosis and platelet studies, cardiovascular and immunological drug screening and cell/bacteria adhesion research.

From Fluxion Biosciences 11 Nov 2009

Researchers find link between two genes involved in cancer formation in humans

Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

11 Nov 2009

Researchers identify new mechanism to create lasting memories; findings may yield potential treatment for memory impairments

Researchers at the Swedish medical university Karolinska Institutet have discovered a mechanism that controls the brain's ability to create lasting memories. In experiments on genetically manipulated mice, they were able to switch on and off the animals' ability to form lasting memories by adding a substance to their drinking water. The findings, which are published in the scientific journal PNAS, are of potential significance to the future treatment of Alzheimer's and stroke.

11 Nov 2009

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.

11 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Potential new drug for lung cancer eliminates tumors in mice

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

11 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

Receptor News and Research

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Positive results from Winston Laboratories' Civamide Patch trial

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Chronic pain patients with depression three times more likely to receive opioid medications

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

Lipid that accumulates in brain cells drives cell death, says research

Scientists to develop a treatment for rare genetic disorder, FOP

Adolor commences clinical testing of its oral mu opioid receptor antagonist

OPKO Health acquires NK-1 compounds from Schering

New microplate for BioFlux live cell imaging workstations

Researchers find link between two genes involved in cancer formation in humans

Researchers identify new mechanism to create lasting memories; findings may yield potential treatment for memory impairments

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sprycel holds hope for treating Src dependent ovarian cancer

Potential new drug for lung cancer eliminates tumors in mice

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News